Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome

References

• Dogra G, Ward N, Croft KD, Mori TA, Barrett PH, Herrmann SE, et al. Oxidant stress in nephrotic syndrome: comparison of F (2)-isoprostanes and plasma antioxidant potential. Nephrol Dial Transplant 2001;16:1626–30.
   PubMed Web of Science ®Google Scholar
• Savin VJ. Mechanisms of proteinuria in noninflammatory glomerular diseases. Am J Kidney Dis 1993;21:347–62.
   PubMed Web of Science ®Google Scholar
• Zima T, Tesar V, Stipek S. The influence of cyclosporine on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 1997;75:464–9.
   PubMed Web of Science ®Google Scholar
• Ueda N, Baliga R, Shah SV. Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndrome. Kidney Int 1996;49:370–3.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Ichikawa J, Fogo A. Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 1991;2:902–12.
   PubMed Web of Science ®Google Scholar
• Clemens MR, Burza-Zanetti Z. Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndrome. Nephron 1989;53:325–9.
   PubMed Web of Science ®Google Scholar
• Bulucu F, Vural A, Aydin A, Sayal A. Oxidative stress status in adults with nephrotic syndrome. Clin Nephrol 2000;53:169–73.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000;7:53–8.
   PubMed Web of Science ®Google Scholar
• Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional HDL. Chem Res Toxicol 2010;23:447–54.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000;28:1717–25.
   PubMed Web of Science ®Google Scholar
• Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136–42.
   PubMed Web of Science ®Google Scholar
• Daugherty A, Rateri DL, Dunn JL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437–44.
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159–65.
   PubMed Web of Science ®Google Scholar
• Ece A, Gurkan F, Kervancıoglu M, Kocamaz H, Güneş A, Atamer Y, et al. Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol 2006;21:545–52.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanisms against activated oxygen toxicity in the blood. Am J Obster Gynecol 1979;135:372–6.
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase. In: , Bergmeyer HU, (ed.). Methods of enzymatic analysis. New York and London: Academic Pres Inc.; 1974. p. 673–7.
   Google Scholar
• Klebanoff SJ, Clark FA. The neutrophil: function and clinical disorders, 1. Amsterdam, The Netherlands: Elsevier/North Holland Biomedical Press; 1978. p. 810.
   Google Scholar
• El-Far MA, Bakr MA, Farahat SE, Abd El-Fattah EA. Glutathione peroxidase activity in patients with renal disorders. Clin Exp Nephrol 2005;9:127–31.
   PubMedGoogle Scholar
• Cheesman KH, Slatter TF. An introduction to free radical biochemistry. Br Med Bull 1993;49:481–93.
   PubMed Web of Science ®Google Scholar
• Alfrey AC. Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 1994;23:183–7.
   PubMed Web of Science ®Google Scholar
• Diamond JR. The role of reactive oxygen species in animal models of glomerular disease. Am J Kidney Dis 1992;19:292–300.
   PubMed Web of Science ®Google Scholar
• Zachwieja J, Bobkowski W, Dobrowolska-Zachwieja A, Zaniew M, Maciejewski J. Decreased antioxidant activity in hypercholesterolemic children with nephrotic syndrome. Med Sci Monit 2003;9:235–9.
   Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;632:801–9.
   Google Scholar
• Guijarro C, Keane WF. Lipid-induced glomerular injury. Nephron 1994;67:1–6.
   PubMed Web of Science ®Google Scholar
• Soyoral YU, Aslan M, Emre H, Begenik H, Erdur FM, Turkel A, et al. Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome. Atherosclerosis 2011;218:243–6.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879–91.
   PubMed Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patiens with acute coronary syndrome. Circulation 2003;108:1440–5.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, VanLente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. New Engl J Med 2003;349:1595–604.
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009;55:1462–70.
   PubMed Web of Science ®Google Scholar
• Hazen SL, Hsu FF, Gaut JP. Modification of proteins and lipids by myeloperoxidase. Methods Enzymol 1999;300:88–105.
   PubMed Web of Science ®Google Scholar
• Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, et al. Myeloperoxidase, a leukocyte derived vascular NO oxidase. Science 2002;296:2391–4.
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535–44.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003;14:353–9.
   PubMed Web of Science ®Google Scholar
• Pawlus J, Hołub M, Kozuch M, Dabrowska M, Dobrzyckı S. Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease. Int Jnl Lab Hem 2010;32:320–8.
   PubMed Web of Science ®Google Scholar
• McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005;111:2798–804.
   PubMed Web of Science ®Google Scholar
• Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006;98:796–9.
   PubMed Web of Science ®Google Scholar
• Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197:615–24.
   PubMed Web of Science ®Google Scholar
• Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, et al. Myeloperoxidase generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005;112:2812–20.
   PubMed Web of Science ®Google Scholar
• Hoy A, Treagoueet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001;9:780–6.
   PubMed Web of Science ®Google Scholar
• Hamm C. A classification of unstable angina revisited. Circulation 2000;102:118–22.
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134–9.
   PubMed Web of Science ®Google Scholar
• Michowitz Y, Kisil S, Guzner-Gur H, Rubinstein A, Wexler D, Sheps D. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart. IMAJ 2008;10:884–8.
   Web of Science ®Google Scholar